Skip Navigation



Annals of Oncology Advance Access published online on April 26, 2005

Annals of Oncology, doi:10.1093/annonc/mdi213
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/7/1094    most recent
mdi213v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Orlando, L.
Right arrow Articles by Goldhirsch, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orlando, L.
Right arrow Articles by Goldhirsch, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received October 22, 2004
Revised February 9, 2005
Accepted February 10, 2005

Original article

Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype

L. Orlando 1*, G. Renne 2, A. Rocca 1, G. Curigliano 1, M. Colleoni 1, G. Severi 3, G. Peruzzotti 1, S. Cinieri 1, G. Viale 2, G. Sanna 1, and A. Goldhirsch 1

1 Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy,
2 Division of Pathology, European Institute of oncology, Milan, Italy and
3 Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy

* To whom correspondence should be addressed.
L. Orlando, E-mail: laura.orlando{at}ieo.it


   Abstract

Background: Medullary carcinoma (MC) of the breast is associated with favorable prognosis compared with other histological types, despite high nuclear grade, fast proliferation and lack of steroid hormone receptor expression. We retrospectively evaluated the clinical relevance of selected immunohistochemical features of tumors in three cohorts of patients with typical medullary (MC), ‘atypical’ medullary (AMC) or ductal (DC) breast carcinoma.

Patients and methods: Evaluation was performed on node-negative tumor specimens from 40 patients who had either MC (12 patients), AMC (nine patients) or DC (19 patients), treated in a single institution. All had no hormonal receptor, Ki-67 ≥30%, G3, expansive pattern of growth and peritumoral lymphocytic infiltration. In addition, p27, p21 and HER2/neu overexpression, p53, cyclin E and E-cadherin expression, presence of apoptotic cells, stromal tenascin (TN), and type of immune cell infiltration (CD3- and CD68-positive cells) were assessed.

Results: No difference in expression of HER2/neu, p21, p27, p53, number of apoptotic cells and CD68-positive cells was detected. Lower levels of stromal TN expression were found in MC compared with DC (P=0.0007), but differences between MC and AMC were not significant (P=0.27). A higher proportion of intratumoral CD3-positive cells was seen in MC than in AMC (P=0.046). No differences were seen between MC and DC (P=0.73). With a median follow-up of 67 months, three patients with DC had relapsed in distant sites, while one patient with AMC had a second primary. Two patients with MC had reappearance of DC in the breast.

Conclusions: The three distinct disease types, selected by having similar high proliferation, had similar expression of cell cycle regulators. The lower expression of TN and massive infiltration of T lymphocytes might both indicate a special interaction between tumor cells and microenvironment, important features for conferring improved prognosis through negligible invasive and metastatic potential to MC. In our series, however, patients with a previous MC are not free from the risk of developing a subsequent DC. Finally, defining AMC as a distinct entity from DC is not justified.

Keywords: breast cancer; medullary phenotype; pathological features.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
G. Huper and J. R. Marks
Isogenic Normal Basal and Luminal Mammary Epithelial Isolated by a Novel Method Show a Differential Response to Ionizing Radiation
Cancer Res., April 1, 2007; 67(7): 2990 - 3001.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. P. Goetz, V. J. Suman, J. N. Ingle, A. M. Nibbe, D. W. Visscher, C. A. Reynolds, W. L. Lingle, M. Erlander, X.-J. Ma, D. C. Sgroi, et al.
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2080 - 2087.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.